Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer

Adenocarcinoma of the Prostate Clinical Trial

Official title: Study of Stereotactic Body Radiotherapy (SBRT) for High-Risk Localized Prostrate Cancer

Status Active, not recruiting

Clinical Trial Summary

This clinical trial studies stereotactic body radiation therapy in treating patients with high-risk prostate cancer that has not spread to nearby lymph nodes or to other parts of the body. Stereotactic body radiation therapy is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Studying quality of life in patients undergoing stereotactic body radiation therapy may help identify the long-term effects of treatment on patients with prostate cancer.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To establish the efficacy of stereotactic body radiation therapy (SBRT) in patients with high-risk localized prostate cancer compared to historical data from clinical trials.

II. To establish the safety with physician-reported outcomes after SBRT in patients with high risk localized prostate cancer.

III. To establish the quality of life with patient-reported validated questionnaires after SBRT in patients with high risk localized prostate cancer.

OUTLINE:

Patients undergo SBRT daily or every other day for a total of 5 fraction not exceeding 14 consecutive days. Patients may also receive androgen deprivation therapy for up to 9 months at the discretion of the treating physician.

After completion of study treatment, patients are followed up every 4 months for 1 year, every 6 months for 5 years, and then every 12 months thereafter. ;

Related Conditions & MeSH terms

• Adenocarcinoma of the Prostate
• Prostatic Neoplasms
• Stage III Prostate Cancer

• NCT number: NCT02296229
• Study type: Interventional
• Source: Jonsson Comprehensive Cancer Center
• Status: Active, not recruiting
• Phase: N/A
• Start date: January 27, 2014
• Completion date: January 27, 2026